FindTrial
Sign In

TAK-981

DRUG5 trials

Sponsors

Takeda, Presage Biosciences

Conditions

Advanced or Metastatic Solid TumorsHead and Neck CancerHematologic NeoplasmsLymphomaLymphoma, Non-HodgkinNeoplasmsRelapsed and/or Refractory Multiple Myeloma (RRMM)

Early Phase 1

Intratumoral Microdosing of TAK-981 in Head and Neck Cancer
CompletedNCT04065555
Presage BiosciencesHead and Neck Cancer
Start: 2020-10-07End: 2022-07-20Updated: 2022-07-29

Phase 1

A Study of TAK-981 in People With Advanced Solid Tumors or Cancers in the Immune System
TerminatedNCT03648372
TakedaHematologic Neoplasms, Lymphoma, Neoplasms
Start: 2018-10-01End: 2023-12-14Updated: 2024-11-19
A Study of TAK-981 Given With Rituximab in Adults With Relapsed or Refractory CD20-Positive Non-Hodgkin Lymphoma
TerminatedNCT04074330
TakedaLymphoma, Non-Hodgkin
Start: 2019-10-15End: 2023-04-26Updated: 2024-06-14
A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors
CompletedNCT04381650
TakedaAdvanced or Metastatic Solid Tumors
Start: 2020-08-17End: 2024-10-29Updated: 2025-12-10
A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM)
TerminatedNCT04776018
TakedaRelapsed and/or Refractory Multiple Myeloma (RRMM)
Start: 2021-04-20End: 2023-11-09Updated: 2024-10-02

Related Papers

Data from A First-In-Human Study of the SUMOylation Inhibitor Subasumstat in Patients with Advanced/Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies
2025-11-19
A First-In-Human Study of the SUMOylation Inhibitor Subasumstat in Patients with Advanced/Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies.
2025-11-01
Abstract CT061: Pharmacodynamic analysis from a phase 1/2 study of subasumstat (TAK-981) as single agent in patients (pts) with advanced/refractory metastatic solid tumors
Cancer Research2024-04-052 citations
569 A CIVO intratumor microdose Phase 0 Trial of subasumstat (TAK-981) in combination with cetuximab or avelumab reveals Type 1 Interferon induction and immune activation in head and neck cancer patients
Regular and Young Investigator Award Abstracts2022-11-013 citations
A phase 1b, multicenter, dose-escalation study of subasumstat (TAK-981) in combination with pembrolizumab in patients (pts) with advanced solid tumors.
Journal of Clinical Oncology2022-06-017 citations
The SUMOylation inhibitor subasumstat potentiates rituximab activity by IFN1-dependent macrophage and NK cell stimulation
Blood2022-02-2866 citations
TAK-981, a First-in-Class SUMO-Activating Enzyme Inhibitor, Combined with Rituximab in Adult Patients (Pts) with CD20-Positive Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL): Phase 1 Data
Blood2021-11-0510 citations
Phase 1b/2 Study of the First-in-Class SUMO-Activating Enzyme Inhibitor TAK-981 in Combination with Monoclonal Antibodies in Patients with Triple-Class Refractory Multiple Myeloma
Blood2021-11-052 citations
476 First-in-human phase 1/2 study of the first-in-class SUMO-activating enzyme inhibitor TAK-981 in patients with advanced or metastatic solid tumors or relapsed/refractory lymphoma: phase 1 results
Regular and Young Investigator Award Abstracts2021-11-0114 citations
A small-molecule SUMOylation inhibitor activates antitumor immune responses and potentiates immune therapies in preclinical models.
2021-09-15105 citations
Phase 1/2 study of the novel SUMOylation inhibitor TAK-981 in adult patients (pts) with advanced or metastatic solid tumors or relapsed/refractory (RR) hematologic malignancies.
Journal of Clinical Oncology2021-05-206 citations
A Phase 1b/2 Study of TAK-981, a First-in-Class Sumoylation Inhibitor, in Combination with Rituximab in Patients with Relapsed/Refractory (r/r) CD20-Positive Non-Hodgkin Lymphoma (NHL)
Blood2019-11-135 citations
Abstract 3252: TAK-981: A first in class SUMO inhibitor in Phase 1 trials that promotes dendritic cell activation, antigen-presentation, and T cell priming
Cancer Research2019-07-0114 citations
Abstract 3079: Pharmacodynamic evaluation of the novel SUMOylation inhibitor TAK-981 in a mouse tumor model
Cancer Research2019-07-017 citations
Abstract 3079: Pharmacodynamic evaluation of the novel SUMOylation inhibitor TAK-981 in a mouse tumor model
Experimental and Molecular Therapeutics2019-07-011 citations
Abstract LB-319: Establishment of automated multiplex immunofluorescence T-cell panel for baseline screening of syngeneic mouse models and evaluation of T-cell infiltration in A20 syngeneic tumors treated with TAK-981, a first-in-class SUMO inhibitor
Cancer Research2019-07-01
Abstract LB-319: Establishment of automated multiplex immunofluorescence T-cell panel for baseline screening of syngeneic mouse models and evaluation of T-cell infiltration in A20 syngeneic tumors treated with TAK-981, a first-in-class SUMO inhibitor
Tumor Biology2019-07-01